welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy
study id #: NCT02034305
condition: Duchenne Muscular Dystrophy
This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP, SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: January 2014
estimated completion: January 2021
phase of development: N/A
size / enrollment: 15
- Spontaneous cough clearance [ Time Frame: Assessed at multiple time points over 30 minutes ]
• Eligible Sexes: male
• Duchenne Muscular Dystrophy OR Becker Muscular Dystrophy
• Need for mechanical ventilation during the day
• Recent (within 2 weeks) lower respiratory tract infection
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrop...it is a randomised, double blind, parall...
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular DystrophyThis study, supported by Charley's Fund,...
MDA Releases Duchenne Fact Sheet, Survey Results Pointing to Need for Knowledge of Clinical Trials and Genetic TestsCiting a persistent need for new treatme...
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dyst...Duchenne Muscular Dystrophy (DMD) is inh...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...